The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, ...

The stock's fall snapped a two-day winning streak.

Last month, Regeneron had agreed to buy the firm for $256 million, beating an earlier $146 million bid from Wojcicki and the ...

Pallas Capital Advisors jumped into the biotech game by purchasing $426,000 worth of Regeneron Pharmaceuticals shares during ...

The French retail bank will buy the Portuguese lender from its majority owner Lone Star in the latest cross-border deal in European banking. A chip-manufacturing spinoff could help solve some of the ...